Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

Allergy Therapeutics appoints ex- Skyepharma man as FD

Peter Jensen, Allergy’s chairman said Wykeham’s experience in life sciences was well suited to Allergy.

Hay fever vaccine specialist Allergy Therapeutics (LON:AGY) has appointed Nick Wykeham as its new finance director.

Wykeham, 51, was group financial controller at Skypharma until August last year, with a stint at ICI business Quest prior to that.

Peter Jensen, Allergy’s chairman said Wykeham’s experience in life sciences was well suited to Allergy.

He replaces Ian Postlethwaite who resigned in March after 14 years with the company and taken up the post of chief financial officer at healthcare company investor NetScientific (LON:NSCI).

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK